Introduction The burden of mild-to-moderate atopic dermatitis (AD) in the United Kingdom (UK) is not well understood. Long-lasting AD flares may lead to systemic inflammation resulting in reversible progression from mild to more severe AD. This study aimed to assess the clinical and economic burden of mild-to-moderate AD in the UK. Methods AD patients were identified in the Health Improvement Network (THIN) from 2013 to 2017 and propensity score matched to non-AD controls by demographics. Patients were identified based on continuous disease activity using validated algorithms and sufficient patient status to fully validate data integrity for the entire period. Mild-to-moderate AD patients were identified by using treatment as a surrogate. Demographics, clinical characteristics and healthcare resource use (HCRU) were obtained from THIN. Literature reviews were conducted to obtain additional outcomes. A cost-of-illness model was developed to extrapolate the burden in 2017 to the UK population and in subsequent years (2018–2022). Results In 2017, the prevalence of mild-to-moderate AD in THIN was 1.28%. These patients reported higher comorbidity rates and significantly higher ( p < 0.0001) HCRU, encompassing mean general practitioner visits (5.57 versus 3.59), AD-related prescriptions (5.85 versus 0.68) and total referrals (0.97 versus 0.82) versus matched non-AD controls. The model projected total HCRU and drug excess costs of €462.99M over the 5 years. The excess cost decreased to €417.35M after excluding patients on very potent topical corticosteroids, who most likely had at least moderate disease. The excess costs increased to €1.21B and €7.06B when considering comorbidity burden and productivity losses, respectively. Conclusion Mild-to-moderate AD patients had higher comorbidity burden, HCRU and cost compared with matched non-AD controls. Overall, UK country-based economic burden was high given partly the high prevalence of this disease. Moreover, productivity burden and comorbidities had considerable impact on the economic burden, which further suggests the importance of optimal disease management. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-021-00519-7.

2018. Age, sex and pharmacotherapy were collected for each patient. AR was calculated using an Anticholinergic Burden web tool Calculator which includes 10 different Anticholinergic scales described in a systematic review. The scales offer final AR scores classified in three groups: low, medium and high, according to the risk categorisation made by the authors of each scale. Higher scores are associated with increased AR. RESULTS: We analysed 111 patients; mean age:73.93±8.35 years, 79.28% males. Mean prescribed drugs: 7.39±3.94. There were 16 patients (14.41%) without risk; 35 (31.53%) with medium risk and 35 (31.53%) with high risk. Twenty-five patients (22.52%) did not receive any anticholinergic drug.According to AR score, 70 patients (58.3%) were taking at least one anticholinergic drug, 39 drugs were involved.We identified 39 drugs with anticholinergic potency being the most common: alprazolam (43.6%), mirtazapine (25.6%), lorazepam (23.1%), sertraline (20.5%). Regarding ATC code, drugs from "N05 psycholeptics" group were mainly involved (30.63%); followed by "N06. Psychoanaleptics" (10.81%)and "A10. Drugs used in diabetes"(9.9%). CONCLUSIONS: A high proportion of elderly patients are at risk of anticholinergics adverse events because of their prescribed treatment. In consequence, detection of AR can be an important strategy for optimising treatment in these patients, particularly in those suffering from dementia. Pharmaceutical care in elderly nursing home enables the optimisation of pharmacotherapy, improving patient safety. REFERENCES AND/OR ACKNOWL-EDGEMENTS All staff of Geriatric-Healthcare Centre.